PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 billion aggregate principal amount of 5.000% senior notes due 2035, in an underwritten public offering. Zoetis intends to use the net proceeds to repay the principal of (i) its 4.500% senior notes due 2025 in the aggregate principal amount of $750 million, (ii) its 5.4
Related Questions
How will the issuance of $1.85 B of senior notes affect Zoetis' capital structure and leverage ratios?
What is the expected impact of the $750 M early redemption of the 4.5 % notes on the company’s cash flow and credit profile?
How do the yields on the 4.150 % 2028 notes and 5.000 % 2035 notes compare to current market rates for comparable senior debt?
Will the refinancing of existing notes improve Zoetis' weighted‑average cost of debt and credit rating?
How might the market price of ZTS react to the announcement of this $1.85 B senior note offering?
What are the potential implications of extending the maturity profile to 2035 for long‑term financing risk?
How does this financing activity compare to recent debt issuances by peer animal‑health and pharmaceutical companies?
Is there any indication that the proceeds will be used for purposes beyond note redemption, such as acquisitions or capex, and how could that affect future earnings?
What is the expected impact on Zoetis' earnings per share (EPS) and free cash flow in the coming years due to the changed interest expense schedule?
Could the increased debt issuance affect the company’s ability to fund future share repurchases or dividend payments?